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Abstract
Background and Objectives: The HIV-1 pandemic has disproportionately affected individuals in resource-constrained
settings. It is important to determine if other prevalent infections affect the progression of HIV-1 in co-infected individuals in
these settings. Some observational studies suggest that helminth infection may adversely affect HIV-1 progression. We
sought to evaluate existing evidence on whether treatment of helminth infection impacts HIV-1 progression.
Review Methods: This review was conducted using the HIV/AIDS Cochrane Review Group (CRG) search strategy and
guidelines. Published and unpublished studies were obtained from The Cochrane Library (Issue 3, 2006), MEDLINE
(November 2006), EMBASE (November 2006), CENTRAL (July 2006), and AIDSEARCH (August 2006). Databases listing
conference abstracts and scanned reference lists were searched, and authors of included studies were contacted. Data
regarding changes in CD4 count, HIV-1 RNA levels, clinical staging and/or mortality were extracted and compared between
helminth-treated and helminth-untreated or helminth-uninfected individuals.
Results: Of 6,384 abstracts identified, 15 met criteria for potential inclusion, of which 5 were eligible for inclusion. In the
single randomized controlled trial (RCT) identified, HIV-1 and schistosomiasis co-infected individuals receiving treatment for
schistosomiasis had a significantly lower change in plasma HIV-1 RNA over three months (20.001 log10 copies/mL)
compared to those receiving no treatment (+0.21 log10 copies/mL), (p=0.03). Four observational studies met inclusion
criteria, and all of these suggested a possible beneficial effect of helminth eradication on plasma HIV-1 RNA levels when
compared to plasma HIV-1 RNA changes prior to helminth treatment or to helminth-uninfected or persistently helminth-
infected individuals. The follow-up duration in these studies ranged from three to six months. The reported magnitude of
effect on HIV-1 RNA was variable, ranging from 0.07–1.05 log10 copies/mL. None of the included studies showed a significant
benefit of helminth treatment on CD4 decline, clinical staging, or mortality.
Conclusion: There are insufficient data available to determine the potential benefit of helminth eradication in HIV-1 and
helminth co-infected adults. Data from a single RCT and multiple observational studies suggest possible benefit in reducing
plasma viral load. The impact of de-worming on markers of HIV-1 progression should be addressed in larger randomized
studies evaluating species-specific effects and with a sufficient duration of follow-up to document potential differences on
clinical outcomes and CD4 decline.
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Introduction
Many individuals living in areas of the world hardest hit by the
HIV-1 epidemic are also infected with other common pathogens.
These infections may have detrimental effects on the host’s ability
to control the HIV-1 virus [1]. Some studies have suggested that
these infections may result in a more rapid progression of HIV-1
disease [2]. Co-infection with other pathogens may lead to a more
rapid destruction of the host immune system and potentially to
earlier progression of HIV-1. Chronic helminth infection may
suppress immune responses directed against HIV-1 and concur-
rent immune activation may directly lead to more rapid loss of
CD4 cells in HIV-1 infected individuals [3].
Of the over 25 million people infected with HIV-1 in Africa, it is
estimated that as many as half of these individuals may be co-
infected with helminths [4,5]. Helminth infection leads to
significant stimulation of the host immune response as these
infections are characterized by the production of eggs, excretory
products, and secretions. Helminth-infected individuals display
increased levels of eosinophilia, increased IgE levels, and a Th2
immune bias [6,7]. Immunoregulation in response to helminth
infection may suppress HIV-1-specific CD4+ and CD8+ pro-
liferation and cytokine production which may compromise control
of HIV-1 replication [8]. Chronic helminth infection has also been
shown to be associated with antigen-specific anergy and
hyporesponsiveness which may also down-regulate control of
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increased cellular susceptibility to HIV-1 infection [10].
Several studies have suggested that helminth co-infection in
HIV-1 infected individuals may result in increased plasma levels of
HIV-1 RNA and possibly in more rapid disease progression
[2,11]. Based on these findings, the hypothesis that helminth
infection may play an important role in the pathogenesis of HIV-1
in Africa was suggested by Bentwich et al [12].
In a study of HIV-1 infected and uninfected individuals in
Ethiopia, helminth co-infection was associated with increased T-cell
activation and anti-helminthic treatment appeared to reduce T-cell
activation. In addition, treatment of helminth infection resulted in
a significant increase in absolute CD4 counts (192 versus 279 cells/
mm
3, p=0.002) [7]. Another study conducted in Ethiopia noted an
association between stool helminth burden and plasma HIV-1 RNA
levels among individuals with helminth co-infection (p,0.001).
Successful treatment of helminth co-infection (clearance of helminth
eggs in stool) led to a significant decrease in HIV-1 plasma viral load
(20.36 log10) in these patients [2]. However, several subsequent
observational studies have shown conflicting results regarding the
impact of anti-helminth therapy on CD4 count, HIV-1 viral load
and clinical disease progression [13,14,15].
As HIV-1 treatment programs are expanded in areas in which
both HIV-1 and helminth infections are prevalent, it is important
to determine whether treating helminth infection can slow HIV-1
disease progression. Mathematical modeling of potential HIV-1
vaccine efficacy suggests that even a modest 0.5 log reduction in
set-point HIV-1 RNA levels could slow the onset of AIDS by
3.5 years and could delay the need for antiretroviral medications
by almost a full year [16]. If anti-helminthic therapy enables HIV-
1 infected individuals to delay initiation of antiretroviral therapy or
reduce morbidity and mortality, the public health significance of
de-worming HIV-1 infected individuals may be substantial.
In this systematic review we evaluated the evidence to date that
treating helminth infection in HIV-1 and helminth co-infected
individuals may impact HIV-1 progression by decreasing HIV-1
virus (HIV-1 RNA), attenuating CD4 decline, or delaying the
onset of symptoms of AIDS.
Methods
We developed a protocol for this review for inclusion in the
Cochrane Database of Systematic Reviews [17]. We included
randomized or quasi-randomized controlled trials assessing the
association between helminth co-infection and HIV-1 disease
progression. We pre-specified that should data from clinical trials
be insufficient, data from observational studies (e.g. cohort, case-
control and cross-sectional studies) would be considered for
inclusion in this review according to the HIV/AIDS CRG policy.
Both interventional clinical trials as well as observational case
control and cohort studies of HIV-1 and helminth co-infected
individuals were included. Studies evaluating the effect of anti-
helminthic therapy on HIV-1 progression were identified. Anti-
helminthic therapy was defined as any intervention approved for
use in the eradication of helminth infection in humans. This
included the benzimidazoles, ivermectin, praziquantel, diethylcar-
bamazine, bithionol, oxamniquine, pyrantel and nitazoxanide.
Control groups included placebo, no treatment, or helminth
uninfected individuals. Studies evaluating changes in CD4 counts
and/or HIV-1 viral load before and after anti-helminthic therapy
were also included. We included studies performed in general or
specific populations, in both hospitals and/or clinics, in any
country and published in any language. Ecological studies were
excluded. The full text of the search strategy employed has been
published previously [17]. The search was conducted by two
reviewers (JW and GJS). There were no disagreements in applying
the inclusion criteria for selected studies.
The primary outcome measures selected were changes in
plasma HIV-1 RNA levels and changes in absolute CD4 counts.
Secondary outcome measures included markers of clinical disease
progression, adverse events, and mortality.
The methodological quality of the included clinical trial was
evaluated independently by both authors (JW and GJS) according
to a validity checklist for clinical trials[18]. The methodological
quality of the included observational studies was assessed using the
Newcastle-Ottawa Quality Assessment Scales for observational
studies (Table 1) [19]. Adequacy of follow up was assessed as
adequate (trials with loss to follow up #20%), inadequate (loss to
follow up above 20%) or unclear (not reported). All outcomes
included in this review were continuous and were assessed with
a standardized mean difference (SMD) and 95% confidence
interval. A narrative synthesis was performed. We did not
statistically pool the outcomes and examine the differences
between fixed and random effects models given the degree of
heterogeneity between the trials.
Results
After an expanded search strategy was employed, we identified
6,384 citations. From this list, we identified 15 potentially relevant
studies, of which 5 were determined to be eligible for this review,
including one randomized controlled trial and four observational
studies (Figure 1). The characteristics of the included studies are
presented in Table 2. All of the included studies were conducted in
Africa and included HIV-1 infected individuals who were treated
for a variety of different helminth infections. Four of the five
studies noted that none of the participants were on antiretroviral
medication while in one study [13], data on antiretroviral therapy
was not provided. In the observational studies, changes in HIV-1
RNA or CD4 were compared between helminth-treated individ-
uals and helminth uninfected controls, or controls in the period
prior to helminth treatment. Three studies also compared changes
in HIV-1 RNA or CD4 between treated individuals who cleared
their helminth infection at follow-up and individuals who
remained infected at follow-up. Unpublished data was requested
from the authors of the included observational studies and
included in this analysis from three of included observational
studies [11,13,14].
The ten excluded studies along with the rationale for exclusion
are presented in Table 3 [1,7,18,20,21,22,23,24,25,26]. Reasons
Author Summary
Many people living in areas of the world most affected by
the HIV/AIDS pandemic are also exposed to other common
infections. Parasitic infections with helminths (intestinal
worms) are common in Africa and affect over half of the
population in some areas. There are plausible biological
reasons why treating helminth infections in people with
HIV may slow down the progression of HIV to AIDS. Thus,
treating people with HIV for helminths in areas with a high
prevalence of both HIV and helminth infections may be
a feasible strategy to help people with HIV delay
progression of their disease or initiation of antiretroviral
therapy. After a comprehensive review of the available
literature, we conclude that there is not enough evidence
to determine whether treating helminth infections in
people with HIV is beneficial.
Helminth/HIV-1 Co-infection, a Systematic Review
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outcome data [1,7,18,20,21,22,25,26], lack of a control compar-
ison group [1,22,26], failure to confirm helminth infection
status[18], and reporting of data already presented in another
included study [23].
The studies were stratified according to study type, i.e. RCT vs.
observational. We had pre-specified in our protocol that meta-
analysis would be performed if data permitted. Given that only
one RCT was identified, the highly heterogeneous comparator
groups and results, as well as the high likelihood of bias in the
observational studies, it was felt that any overall summary statistic
would be misleading and a meta-analysis was not performed.
Instead, we evaluated the direction and consistency of effect,
assessing the likelihood of bias for each included study and
investigating factors that may explain the differences observed
between the studies. Studies were evaluated using the standardized
mean difference (SMD=Difference in mean outcome between
groups/Standard deviation of outcome among participants) [27].
The results of the single randomized control trial demonstrated
a statistically significant benefit on plasma HIV-1 RNA levels with
Table 1. Assessment of quality of cohort studies
Study External Validity Performance Bias Detection Bias Attrition Bias Selection Bias
Description of
assessment criteria
How was sampling
conducted (census,
random, etc.) and were
at least 80% of those
eligible to participate in
all groups recruited?
Was the same method
of ascertainment used in
cases and controls?
How were HIV-1 and
helminth infection status
ascertained and confirmed
and were assessors of
outcome measures
blinded to intervention
groups?
Were all groups followed
for the same time frame
and were at least 80% of
participants in all groups
included in the final
analysis?
How were cases selected
and were controls selected
from the same population
as the cases?
Brown 2004 ** **
Elliott 2003 ** ** ** **
Wolday 2002 ** ** **
Modjarrad 2005 ** ** **
**study design adequate to minimize role of bias
doi:10.1371/journal.pntd.0000102.t001
Figure 1. Flow diagram of study selection process in QUOROM format.
doi:10.1371/journal.pntd.0000102.g001
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compared to no treatment over 3-months of follow-up (Figure 2)
[11]. Individuals in the treatment group had minimal change in
plasma viral load over three months of follow up (20.001 log10
copies/mL) compared to an increase in those who did not receive
treatment during this period (0.21 log10 copies/mL), (p=0.03).
This trial noted a statistically significant benefit on CD4 count
with treatment when both HIV-1 infected and HIV-1 uninfected
individuals were included, with a non-significant trend for
a difference between the two study arms when limited to HIV-1
infected individuals (treatment resulted in a 1.7 cells/mL mean
decline compared to a 35.2 cells/mL mean decline in the untreated
group (p=0.17) (Unpublished data provided by author)) (Figure 3).
This study also evaluated differences in CDC clinical staging
between the treated and untreated group. At the 3-month visit,
there were no differences with regard to the number of individuals
in CDC stage A, B or C (43:20:1 for the treatment arm compared
to 44:20:2 in the untreated arm) although the study was
underpowered for this assessment.
We stratified the four additional observational studies by
outcome variable (HIV-1 RNA or CD4 count) and by comparator
group (helminth-uninfected controls, same individuals during
interval prior to helminth treatment, or individuals who failed to
clear helminths at follow-up).
Study Results Comparing Changes in HIV-1 RNA Levels
Helminth-treated versus helminth-uninfected con-
trols. Three observational studies presented data comparing
treated HIV-1 helminth co-infected individuals to HIV-1 infected
helminth-uninfected controls [2,13,15] (Figure 2). The results of all
of these studies were in the direction of a benefit in reducing
plasma HIV-1 RNA viral load with treatment of helminth co-
infection. In the study by Brown et al, participants were screened
for helminths and treated with albendazole regardless of helminth
infection status. In the other 2 studies, helminth-uninfected partici-
pants did not receive anti-helminthics. Treatment of helminth
infected participants in the Modjarrad study included both
albendazole and praziquantel. The helminth-treated cohort size
in these studies ranged from 13 to 163 participants and the
helminth-uninfected cohort size ranged from 9 to 140 participants.
Follow-up was between 3 and 6 months. Helminth-treated
participants had HIV-1 RNA changes ranging from 20.36 log10
to +0.06 log10 copies/ml following treatment; the standard
mean difference in HIV-1 RNA between helminth-treated and
the helminth-uninfected individuals followed over the same
period ranged from 20.19 to 20.73, all in the direction of
decreased HIV-1 RNA or lower plasma HIV-1 RNA increase in
helminth-treated individuals compared to helminth-uninfected
comparators.
Participants clearing infection at follow up compared to
participants with continued infection at follow up. Three
observational studies compared individuals who cleared their
initial helminth infection following treatment to those who were
helminth-infected at follow-up (Figure 2) [2,13,14]. Two studies
showed a trend towards a beneficial effect on plasma viral load with
the successful treatment of helminth infection while one study did
not. These cohorts included between 13 and 93 individuals who
cleared their helminth infection and between 6 and 70 comparators
who failed to clear helminth infection. Change in plasma HIV-1
RNA ranged from 20.36 to +0.11 log10 copies/ml during 3 to
6 months of follow-up in those who cleared their helminth infection
versus changes of 20.03 to +0.69 log10 copies/ml in those who did
not (standard mean difference of 20.14 to 21.41).
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Helminth-uninfected controls. Changes in CD4 counts
were compared between individuals treated for helminth infection
and individuals who were not infected with helminths at baseline
in 3 studies (Figure 3) [13,14,15]. While there appeared to be
a beneficial effect of treatment on CD4 count in all of these
studies, none were statistically significant. Over 3–6 months of
follow-up, helminth-treated individuals experienced mean
decreases in CD4 counts of 29–48 cells/mL (cohorts of between
30 and 177 individuals) while decreases among individuals without
helminth infection ranged from 50–56 cells/mL over the same
period (cohorts of between 43 and 153 individuals). The
standardized mean difference ranged from 20.01 to 20.23 for
these comparisons.
Changes in CD4 counts within individuals prior to and
after helminth eradication therapy. Two observational
studies compared changes in CD4 counts in a 6 month period
prior to treatment of helminths to changes observed during follow-
up post-treatment in the same individuals [13,14]. Neither of these
studies showed significant differences in CD4 count changes before
and after treatment of helminth co-infection. In the 6 month
period preceding helminth treatment, one study noted a CD4
decline of 36 cells/mL in 177 individuals and a decline of 42 cells/
mL in the 6 months following treatment while the other study
documented a rise in mean CD4 count of 3 cells/mL among 30
individuals prior to treatment versus a decline of 29 cells/mL
following treatment (unpublished data provided by authors).
Participants clearing infection at follow up compared
to participants with continued infection at follow
up. Changes in CD4 counts between helminth co-infected
individuals who cleared their infection following treatment and
those who were infected with helminths at the follow-up visit were
compared in two studies [13,14]. In contrast to the expected
direction of effect, one study noted that among 104 individuals
who cleared their helminth infection, there was a mean decline of
54 cells/mL compared to a decline of 24 cells/mL among 73
individuals with persistent helminth infection (p=0.14). In another
study, 21 individuals who cleared their helminth infection had
a median increase in CD4 count of 1 cells/mL compared to an
increase of 2 cells/mL in 13 individuals with persistent infection
(unpublished data provided by authors).
Mortality. Mortality data were presented in three of the
included studies. In one study, there were 13 deaths over 6 months
of follow-up among 144 helminth-treated individuals (mortality
rate of 90.4 cases/1000 person-years, 95% CI 52.5–155.6)
compared to 13 deaths among 122 helminth-uninfected
individuals (mortality rate 106.4 cases/1000 person years, 95%
CI 61.8–183.3), (difference in mortality, p=0.68) [13]. In a smaller
Figure 2. Forest plot showing changes in Log10 HIV-1 RNA between treatment group and selected comparator groups.
doi:10.1371/journal.pntd.0000102.g002
Figure 3. Forest plot showing changes in CD4 counts between treatment group and selected comparator groups.
doi:10.1371/journal.pntd.0000102.g003
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individuals and 2 deaths among the 25 helminth-uninfected
individuals [2]. Finally, in a third study there was 1 death in each
of the groups (helminth-treated and helminth-uninfected) [15].
Helminth species-specific effects. The RCT was the only
study designed to evaluate the effect of treating a specific helminth
(schistosomiasis). There were differences in species-specific preval-
ence rates reported in each of the included studies (Table 2). The
studies by Elliott et al, Brown et al and Modjarrad et al reported
differences between helminth species although all were under-
powered to detect potentially meaningful effects by individual
species. Elliott et al also reported a significant decline in log10
HIV-1 RNA levels among individuals with schistosomiasis (n=24)
between 5 weeks following therapy and the 4 month follow-up
visit (p=0.01). In contrast to this, Brown et al reported signifi-
cantly greater decreases in CD4 counts in individuals who
successfully cleared their schistosomiasis infection at 6 months
(n=105, mean decrease of 59.8 cells/mL) compared to those who
remained persistently infected with schistosomes (n=54, mean
decrease of 15.5 cells/mL) (p=0.05), Brown et al also found that
among Mansonella perstans infected subjects, persistent infection at
follow up (n=22) was associated with a decrease from 4.86 to 4.67
log10 HIV-1 RNA (p=0.009).
Discussion
It has been suggested that de-worming is unlikely to have an
effect on HIV-1 progression in co-infected individuals [22].
However, to date there has been only one randomized controlled
trial evaluating the potential benefit of treating helminth co-
infection in HIV-1 infected individuals which was limited to
evaluation of schistosomiasis co-infection. The results of our
systematic review including the single randomized clinical trial and
four observational studies demonstrate that there are insufficient
data regarding the potential impact of de-worming on HIV-1
progression in co-infected individuals.
The only RCT conducted to date demonstrated a statistically
and clinically significant difference in change in HIV-1 RNA levels
(0.21 log10 HIV-1 RNA) in treated versus untreated individuals
with schistosomiasis [11]. This study failed to show significant
differences in changes in CD4 counts or clinical staging between
groups. The study was limited by a lack of allocation concealment,
a short follow-up interval (3 months), and differences at baseline in
gender distribution, CD4 counts and plasma HIV-1 viral loads
between randomization groups. In the 4 observational studies
eligible for inclusion in this review, there was also a trend towards
a beneficial effect of helminth treatment on HIV-1 RNA levels in
co-infected individuals. Again, de-worming did not appear to exert
a benefit on CD4 count decline or mortality in these studies, and
some studies found greater CD4 decline following successful
helminth clearance when compared to persistently infected
individuals. Together, the cumulative available evidence suggests
a possible benefit of de-worming on plasma HIV-1 RNA levels but
not CD4 counts or clinical status over a short period of follow-up.
In the observational studies reviewed, groups of helminth-
treated individuals were compared to 3 different types of ‘‘control’’
groups, all of which were likely to differ at baseline from the group
with helminth infection in which the intervention was adminis-
tered. Helminth-infected individuals may have pre-existing
differences in behavioral, social, nutritional and biological factors
that led to helminth infection and may also result in faster HIV-1
progression. A comparator group of helminth co-infected indivi-
duals who did not clear their helminth infection is similarly subject
to bias, as helminth clearance may be directly related to the
capacity of the host immune system to handle such infections,
which may also correlate with control of HIV-1. Comparing
individual data from a period of time prior to de-worming to data
following therapy is also subject to limitations. Individuals may
acquire helminth infection during the period between the initial
measurement of CD4 count or HIV-1 RNA and the de-worming
visit and this could result in misclassification of the exposure. In
addition, rates of change in CD4 count and viral load in HIV-1
infected individuals differ over time, making it difficult to compare
changes in these parameters at two different periods within an
individual. These limitations compromise the strength of the
evidence regarding treatment effect and highlight the need for
randomized placebo-controlled trials to determine effects of anti-
helminthics on HIV-1 progression.
There are important possible interactions between helminths and
HIV-1 that may be dependent on the intensity of helminth infection
ordifferencesintheinfecting helminthspecies.Helminthburden has
been correlated with HIV-1 RNA levels in HIV-1 co-infected
individuals and may be an important factor in determining the
extent to which helminths affect HIV-1 progression [2]. In addition,
helminth species differ in their level of tissue invasiveness, level of
resulting host immune activation and other factors which may
explain observed differences in the interactions between HIV-1 and
various helminths seen in observational studies [8].
All of the included studies were limited by short follow-up
duration. The finding of changes in HIV-1 RNA levels despite the
short duration of follow-up in these studies is perhaps more
biologically plausible than a finding of changes in clinical staging
or CD4 counts. Helminth infection may directly suppress the Th1
response leading to a reduction in virus specific CD8+ cytotoxic T
lymphocytes (CTL’s) [28,29]. Plasma HIV-1 viral load is directly
related to HIV-1 specific CTL responses in humans and
a reduction in CTL response is associated with a more rapid
progression of HIV-1 disease [30,31,32,33,34]. It is plausible that
the changes in immune control of HIV-1 replication could lead to
more immediate changes in HIV-1 RNA levels following helminth
infection or eradication. In contrast, CD4 decline appears more
related to immune activation status and changes in regulatory T
cell expression and function which may resolve more slowly
following treatment of helminth infection [8].
The ideal study design to determine anti-helminth treatment
effect on HIV-1 progression is a randomized clinical trial. Thus,
randomization to immediate versus deferred treatment was used in
the single RCT of schistosomiasis eradication. However, the short
period of follow-up ethically feasible for treatment deferral limits
ability to determine longer term effects of anti-helminthics on
HIV-1 progression. Randomization without determination of
helminth-infection status may be an alternative study design to
determine if anti-helminthics should be empirically provided for
individuals in HIV-1 care programs in areas of high helminth
prevalence. This approach does not require helminth-screening
and may enable determination of helminth treatment effects over
longer periods but would require sufficient helminth prevalence to
achieve power to detect effect.
The results of this systematic review suggest there are
insufficient data to determine whether de-worming patients with
HIV-1 has a beneficial effect on HIV-1 viral load, CD4 count or
clinical progression. There are significant limitations to all of the
studies identified and available data do not support empiric anti-
helminthic therapy or routine helminth screening of HIV-1
infected individuals. However, the cumulative evidence suggests
that de-worming HIV-1 infected individuals may have beneficial
effects on plasma HIV-1 RNA viral load. There is need for large
randomized controlled trials with longer follow-up duration in
Helminth/HIV-1 Co-infection, a Systematic Review
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populations with a high prevalence of both helminth and HIV-1
infection.
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